NCT05355168View on ClinicalTrials.gov

Neoadjuvant CRT Combined With Camrelizumab and Nimotuzumab for Initially Inoperable Patients With Esophageal Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

November 1, 2021

Primary Completion Date

December 31, 2023

Study Completion Date

March 31, 2024

Conditions
Toxicity, Drug
Interventions
DRUG

neoadjuvant chemoradiotherapy combined with Camrelizumab and Nimotuzumab followed by surgery

neoadjuvant chemoradiotherapy combined with Camrelizumab and Nimotuzumab followed by surgery

Trial Locations (1)

Unknown

Anhui Provicial Hospital, Hefei

All Listed Sponsors
lead

Anhui Provincial Hospital

OTHER_GOV

NCT05355168 - Neoadjuvant CRT Combined With Camrelizumab and Nimotuzumab for Initially Inoperable Patients With Esophageal Carcinoma | Biotech Hunter | Biotech Hunter